Wednesday, February 4, 2026 at 1:34 PM
AbbVie reported higher fourth-quarter revenue driven by strong demand for its immunology drugs Skyrizi and Rinvoq, while also experiencing a smaller decline in sales of its older drug Humira.
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
